<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2212211496
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Empaveli 1080 mg per 20 ml 8 vials
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PEGCETACOPLAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        54
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        146972.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Cangene BioPharma Inc. (CBI) " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Cangene BioPharma Inc. (CBI) 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 594]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Arabian Trade House
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SWEDISH ORPHAN BIOVITRUM INTERNATIONAL AB
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>EMPAVELI is a medicine containing the active substance pegcetacoplan used to treat adults with a disease called paroxysmal nocturnal hemoglobinuria (PNH).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use EMPAVELI</strong></p><ul><li>if you are allergic to pegcetacoplan or any of the other ingredients of this medicine (listed in section 6).</li><li>if you have a serious infection caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae type B when you are starting EMPAVELI treatment.</li></ul><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor, pharmacist or nurse before using EMPAVELI.</p><p>&nbsp;</p><p><u>Serious infections caused by encapsulated bacteria</u></p><p>EMPAVELI is a medicine that affects your immune system. EMPAVELI may lower the ability of your immune system to fight infections.</p><p>&nbsp;</p><p>EMPAVELI increases your chance of getting serious infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae type B. These serious infections may quickly become life-threatening or cause death if not recognized and treated early.</p><p>&nbsp;</p><ul><li>You must complete or be up to date with the vaccines against Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B at least 2 weeks before your first dose of EMPAVELI.</li><li>If you have not completed your vaccines and EMPAVELI must be started right away, you should receive the required vaccines as soon as possible.</li><li>If you have not been vaccinated and EMPAVELI must be started right away, you should receive antibiotics to take for as long as your doctor tells you.</li><li>If you have been vaccinated against these bacteria in the past, you might need additional vaccines before starting EMPAVELI. Your doctor will decide if you need additional vaccines.</li><li>Vaccines do not prevent all infections caused by encapsulated bacteria. Call your doctor or get emergency medical care right away if you get any of these signs and symptoms of a serious infection:</li></ul><p style="margin-left:40px">- fever with or without shivers or the chills</p><p style="margin-left:40px">- fever with chest pain and cough</p><p style="margin-left:40px">- fever with high heart rate</p><p style="margin-left:40px">- headache and a fever</p><p style="margin-left:40px">- confusion</p><p style="margin-left:40px">- clammy skin</p><p style="margin-left:40px">- fever and a rash</p><p style="margin-left:40px">- fever with breathlessness or fast breathing</p><p style="margin-left:40px">- headache with nausea (feeling sick) or vomiting</p><p style="margin-left:40px">- headache with a stiff neck or stiff back</p><p style="margin-left:40px">- body aches with flulike symptoms</p><p style="margin-left:40px">- eyes sensitive to light</p><p>&nbsp;</p><p><u>Anaphylaxis and infusion-related reactions</u></p><p>Allergic reactions can happen during your EMPAVELI infusion. Stop your EMPAVELI infusion and tell your doctor or get emergency medical care right away if you get any of these symptoms during your EMPAVELI infusion:</p><p style="margin-left:40px">- difficulty breathing including shortness of breath and wheezing<br />- chest pain or chest tightness<br />- swollen tongue or throat<br />- feeling faint<br />- rapid heart rate<br />- skin reactions, including hives and itching<br />- nausea or vomiting<br />- confusion and anxiety&nbsp;&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p>It is not known if EMPAVELI is safe and effective in children or adolescents.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and EMPAVELI</strong></p><p>Tell your doctor or pharmacist if you are using or have recently used or might use any other medicines.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>EMPAVELI may harm your unborn baby. Females who are able to become pregnant should have a pregnancy test before starting treatment with EMPAVELI.</p><p>Females who are able to become pregnant should use an effective method of birth control (contraception) during treatment with EMPAVELI and for 40 days after the last dose.</p><p>If you are breast-feeding or plan to breastfeed. It is not known if EMPAVELI passes into your breast milk. You should not breast-feed during treatment with EMPAVELI and for 40 days after the last dose.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>This medicine has no or negligible influence on the ability to drive and use machines.</p><p>&nbsp;</p><p><strong>EMPAVELI contains sorbitol</strong></p><p>Sorbitol is a source of fructose. If your doctor has told you that you have an intolerance to some sugars or if you have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which a person cannot break down fructose , talk to your doctor before you take or receive this medicine.</p><p>&nbsp;</p><p><strong>EMPAVELI contains sodium</strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p>&nbsp;</p><p><strong>Dose</strong></p><p>EMPAVELI is intended to be given as an infusion (drip) under the skin using an infusion pump. EMPAVELI is given by an infusion 2 times each week. If there is an increase in your LDH, an enzyme in your blood, your doctor may tell you to take EMPAVELI every 3 days.</p><p>If you are changing treatment from eculizumab to EMPAVELI, you should continue eculizumab for 4 weeks after your first dose of EMPAVELI. After 4 weeks, you should stop treatment with eculizumab. If you are changing treatment from ravulizumab to EMPAVELI, you should take your starting dose of EMPAVELI no more than 4 weeks after your last dose of ravulizumab.</p><p><strong>&nbsp;</strong></p><p><strong>Method and route of administration</strong></p><p>EMPAVELI is intended for use under the guidance of a doctor. After proper training in infusion (drip) under the skin, you may self-administer, or your caregiver may administer EMPAVELI, if a doctor determines that it is appropriate.</p><p>&nbsp;</p><p><strong>Infusion rate(s)</strong></p><p>The typical infusion time is approximately 30 minutes if you use 2 infusion sites or approximately 60 minutes if using 1 site.</p><p>&nbsp;</p><p><strong>If you use more EMPAVELI than you should</strong></p><p>If you have used more EMPAVELI than you should (either by using too much on a single occasion or by using it too frequently), talk to a doctor or pharmacist immediately.</p><p><em>&nbsp;</em></p><p><strong>If you forget to use EMPAVELI</strong></p><p>If you miss a dose of EMPAVELI, take the missed dose as soon as possible. Take your next dose at your regularly scheduled time.</p><p><strong>&nbsp;</strong></p><p><strong>If you stop using EMPAVELI</strong></p><p>If you have PNH and you stop taking EMPAVELI, your doctor will need to monitor you closely for at least 8 weeks after stopping EMPAVELI. Stopping treatment with EMPAVELI may cause a breakdown of red blood cells due to PNH. Symptoms and problems that can happen due to red blood cell breakdown include:</p><ul><li>decreased hemoglobin level in your blood</li><li>blood in your urine</li><li>shortness of breath</li><li>trouble swallowing</li><li>tiredness</li><li>pain in the stomach (abdomen)</li><li>blood clots</li><li>erectile dysfunction</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>EMPAVELI can cause serious side effects including: </strong></p><p><u>Serious infections</u></p><p>If you experience any of the infection symptoms, see section 2, you should immediately inform your doctor.</p><p><strong>&nbsp;</strong></p><p><u>Allergic reactions</u></p><p>If a severe hypersensitivity reaction (e.g., facial swelling, rash) occurs, see section 2, discontinue EMPAVELI infusion immediately and contact your doctor.</p><p>&nbsp;</p><p>If you are not sure what the side effects below are, ask your doctor to explain them to you.</p><p><strong>&nbsp;</strong></p><p><strong>Very common </strong>(may affect more than 1 in 10 people):<strong> </strong></p><ul><li>injection-site reactions</li><li>infections</li><li>diarrhea</li><li>pain in the stomach (abdomen)</li><li>respiratory tract infection</li><li>pain in the arms, hands, legs or feet</li><li>low potassium in blood</li><li>tiredness (fatigue)</li><li>viral infection</li><li>cough</li><li>joint pain</li><li>dizziness</li><li>headache</li><li>rash</li></ul><p>&nbsp;</p><p><strong>Common</strong> (may affect up to 1 in 10 people):</p><ul><li>chest pain</li><li>back pain</li><li>high blood pressure</li><li>intestinal ischemia</li><li>biliary sepsis</li><li>hypersensitivity pneumonitis</li></ul><p>&nbsp;</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.</p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s): </strong></p><ul><li><strong>Saudi Arabia:</strong><strong>&nbsp;</strong></li></ul><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC):<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p><ul><li><strong>United Arab Emirates</strong></li></ul><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Pharmacovigilance and Medical Device Section:<br />Postal code: 1853<br />Telephone: 80011111<br />E-mail: pv@mohap.gov.ae</p><p>Drug Department<br />Ministry of Health and Prevention<br />Dubai</p></td></tr></tbody></table><p>&nbsp;</p><ul><li><strong>Other GCC States:</strong><strong> </strong></li></ul><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>- Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Store in a refrigerator (2 &deg;C &ndash; 8 &deg;C).</p><p>Store in the original package in order to protect from light.</p><p>Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is pegcetacoplan. Each vial contains 54 mg/mL of pegcetacoplan.</p><p>The other ingredients are: sorbitol, glacial acetic acid, sodium acetate trihydrate, water for injection. EMPAVELI may also contain sodium hydroxide and/or additional glacial acetic acid for pH adjustment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                EMPAVELI is a clear, colourless to slightly yellowish solution for subcutaneous infusion supplied as 1080 mg per 20 mL (54 mg/mL) solution in 20-mL single-dose vials.

EMPAVELI comes in a pack of 1 vial or a multipack of 1 × 8 vials.

Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder &amp; Batch Releaser:</strong></p><p>Swedish Orphan Biovitrum AB (publ)</p><p>SE-112 76 Stockholm</p><p>Sweden.</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Cangene BioPharma, LLC</p><p>1111 South Paca Street</p><p>Baltimore, MD 21230, USA.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;<strong>Council of Arab Health Ministers</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>This is a Medicament</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you. </em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament. </em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The doctor and the pharmacist are the experts in medicines, their benefits and risks.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not by yourself interrupt the period of treatment prescribed for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Do not repeat the same prescription without consulting your doctor. </em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Keep all medicaments out of reach of children. </em></p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table><p>Council of Arab Health Ministers</p><p>Union of Arab Pharmacists</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This Leaflet was last revised in Feb 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>إيمبافيلي دواء يستخدم لعلاج البالغين المصابين بمرض يسمى البيلة الهيموغلوبينية الانتيابية الليلية (PNH).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم إيمبافيلي</strong></p><ul dir="rtl"><li>إذا كنت تعاني حساسية تجاه بيجسيتاكوبلان أو أي من المكونات الأخرى في هذا الدواء (والواردة في القسم 6).</li><li>إذا كنت مصابًا بعدوى خطيرة التي تسببها البكتيريا المغلفة، بما في ذلك المكورات العنقودية الرئوية أو النيسرية السحائية أو المستدمية النزلية من النوع &quot;ب&quot; عند بدء العلاج بإمبافيلي.</li></ul><p>&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong><strong> </strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرض(ة) قبل استخدام عقار إيمبافيلي.</p><p>&nbsp;</p><p dir="RTL"><u>العدوى الخطيرة التي تسببها البكتيريا المغلفة</u></p><p dir="RTL">إيمبافيلي هو دواء يؤثر على جهازك المناعي. يمكن أن يقلل إيمبافيلي من قدرة جهازك المناعي على مكافحة العدوى.</p><p>&nbsp;</p><p dir="RTL">يزيد إمبافيلي من فرصتك في الإصابة بالعدوى الخطيرة التي تسببها البكتيريا المغلفة، بما في ذلك المكورات العقدية الرئوية والنيسرية السحائية والمستدمية النزلية من النوع &quot;ب&quot;. وقد تصبح هذه العدوى الخطيرة مهددة للحياة بسرعة أو تسبب الوفاة إذا لم يتم التعرف عليها وعلاجها مبكرًا.</p><ul><li>يجب عليك إكمال أو تحديث اللقاحات ضد المكورات العقدية الرئوية والنيسرية السحائية والمستدمية النزلية من النوع &quot;ب&quot; قبل أسبوعين على الأقل من جرعتك الأولى من إيمبافيلي.</li><li>إذا لم تكن قد استكملت لقاحاتك ويجب البدء في علاج إيمبافيلي على الفور، فيجب أن تتلقى اللقاحات المطلوبة في أقرب وقت ممكن.</li><li>إذا لم يتم تطعيمك ويجب البدء في علاج إيمبافيلي على الفور، فيجب أن تتلقى المضادات الحيوية التي يجب عليك تناولها طوال المدة التي أخبرك بها طبيبك.</li><li>إذا تم تطعيمك ضد هذه البكتيريا في الماضي، فقد تحتاج إلى لقاحات إضافية قبل بدء استخدام إيمبافيلي. سيقرر الطبيب ما إذا كنت بحاجة إلى تطعيمات إضافية.</li><li>لا تمنع اللقاحات جميع أنواع العدوى التي تسببها البكتيريا المغلفة. اتصل بالطبيب أو احصل على رعاية طبية طارئة على الفور إذا ظهرت عليك أي من العلامات والأعراض التالية لعدوى خطيرة:</li></ul><p dir="RTL" style="margin-right:40px">- حمى مع رجفة أو قشعريرة، أو بدونهما<br />- حمى مع ألم في الصدر وسعال<br />- حمى مع ارتفاع معدل ضربات القلب<br />- صداع وحمى<br />- الارتباك<br />- رطوبة الجلد<br />- حمى وطفح جلدي<br />- حمى مع قصر النفس أو تنفس سريع<br />- صداع مع غثيان أو قيء<br />- صداع مع تيبس الرقبة أو تيبس الظهر<br />- آلام في العضلات مصحوبة بأعراض تشبه الانفلونزا<br />- حساسية العينين للضوء</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحساسية المفرطة والتفاعلات المرتبطة بالتسريب</strong><strong>:</strong></p><p dir="RTL">يمكن أن تحدث ردود فعل تحسسية أثناء تسريب إيمبافيلي. أوقف تسريب إيمبافيلي وأخبر طبيبك أو احصل على رعاية طبية طارئة فورًا إذا ظهرت لك أي من هذه الأعراض أثناء تسريب إيمبافيلي:</p><p dir="RTL" style="margin-right:40px">- صعوبة في التنفس بما في ذلك قصر النفس والصفير عند التنفس<br />- ألم في الصدر أو ضيق في الصدر<br />- انتفاخ اللسان أو الحلق<br />- الشعور بالإغماء<br />- سرعة دقات القلب<br />- ردود فعل تحسسية في الجلد ، بما في ذلك الشرى وحكة في الجلد<br />- الغثيان أو القيء<br />- الارتباك والقلق</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">من غير المعروف ما إذا كان عقار إيمبافيلي آمنًا وفعالًا في الأطفال أو المراهقين.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى وإيمبافيلي</strong></p><p dir="RTL">أخبر الطبيب أو الصيدلي إن كنت تستخدم حاليًا أو إن استخدمت مؤخرًا أي أدوية أخرى، أو إن كانت هناك احتمالات لأن تستخدم أي أدوية أخرى.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p>إذا كنت حاملاً أو مرضعة، أو تعتقدين أنك حامل، أو تخططين لإنجاب طفل، فاستشيري طبيبك قبل تناول هذا الدواء.</p><p>قد يؤذي إيمبافيلي الجنين. يجب على النساء القادرات على الحمل إجراء اختبار الحمل قبل بدء العلاج باستخدام إيمبافيلي.</p><p>يجب على النساء القادرات على الحمل استخدام وسيلة فعالة لتحديد النسل (منع الحمل) أثناء العلاج باستخدام إيمبافيلي ولمدة 40 يومًا بعد الجرعة الأخيرة.</p><p>إذا كنت مرضعة أو تخططين للرضاعة الطبيعية. من غير المعروف ما إذا كان إيمبافيلي يمر في حليب الأم. يجب تجنب الرضاعة الطبيعية أثناء العلاج بـ إيمبافيلي ولمدة 40 يومًا بعد الجرعة الأخيرة.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">هذا الدواء لا يكاد يكون له تأثير على القدرة على القيادة واستخدام الآلات.</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي إيمبافيلي على السوربيتول</strong></p><p dir="RTL">السوربيتول مصدر للفركتوز. إذا أخبرك طبيبك أنك تعاني من عدم تحمل بعض السكريات أو إذا تم تشخيص إصابتك بعدم تحمل الفركتوز الموروث (HFI)، وهو اضطراب وراثي نادر لا يستطيع فيه جسم الشخص تكسير الفركتوز، فتحدث إلى طبيبك قبل استخدامك أو تلقيك لهذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي إيمبافيلي على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 ملي مول من الصوديوم (23 ملجم) لكل جرعة، ويمكن القول بأنه خالي من الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم دومًا هذا الدواء كما أخبرك الطبيب بالضبط. راجع الطبيب عند أي شك.</p><p>&nbsp;</p><p dir="RTL"><strong>الجرعة</strong></p><p>من المفترض أن يتم إعطاء إيمبافيلي في شكل تسريب (بالتقطير) تحت الجلد باستخدام مضخة التسريب. يتم إعطاء إيمبافيلي بالتسريب مرتين كل أسبوع. إذا كانت هناك زيادة في لاكتات ديهيدروجيناز (LDH)، وهو إنزيم في دمك، فقد يطلب منك الطبيب استخدام إيمبافيلي كل 3 أيام.</p><p>إذا كنت تقوم بتغيير العلاج من عقار إيكوليزوماب إلى إيمبافيلي، فيجب أن تستمر في استخدام عقار إيكوليزوماب لمدة 4 أسابيع بعد جرعتك الأولى من إيمبافيلي. بعد 4 أسابيع، يجب التوقف عن العلاج باستخدام عقار إيكوليزوماب.</p><p>إذا كنت تقوم بتغيير العلاج من دواء رافيوليزوماب إلى إيمبافيلي، فيجب أن تستخدم الجرعة الأولى من عقار إيمبافيلي بعد مدة لا تزيد عن 4 أسابيع من آخر جرعة من رافيوليزوماب.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>طريقة الاستخدام</strong></p><p dir="RTL">ينبغي استخدام إيمبافيلي تحت إشراف الطبيب. بعد التدريب المناسب على التسريب (بالتقطير) تحت الجلد، يمكنك إعطائه لنفسك، أو قد يقوم مقدم الرعاية الخاص بك بإعطاء إيمبافيلي، إذا قرر الطبيب أن ذلك مناسب.</p><p>&nbsp;</p><p dir="RTL"><strong>معدل (معدلات) التسريب</strong></p><p dir="RTL">تبلغ مدة التسريب المعتادة حوالي 30 دقيقة إذا كنت تستخدم موقعين للتسريب أو حوالي 60 دقيقة إذا كنت تستخدم موقعًا واحدًا.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا استخدمت جرعة أكبر مما ينبغي من إيمبافيلي</strong></p><p dir="RTL">إذا استخدمت كمية أكثر مما ينبغي من عقار إيمبافيلي (إما عن طريق الإفراط في استخدامه في مرة واحدة أو باستخدامه بمعدل أكثر من اللازم)، فاستشر الطبيب أو الصيدلي على الفور.</p><p><em>&nbsp;</em></p><p dir="RTL"><strong>إذا نسيت استخدام إيمبافيلي</strong></p><p dir="RTL">إذا فاتتك جرعة من عقار إيمبافيلي، فتناول الجرعة الفائتة في أسرع وقت ممكن. استخدم جرعتك التالية في الوقت المحدد لها بانتظام.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا توقفت عن استخدام إيمبافيلي</strong></p><p dir="RTL">إذا كنت مصابًا بالبيلة الهيموغلوبينية الانتيابية الليلية (PNH) وتوقفت عن استخدام إيمبافيلي، فسيحتاج طبيبك إلى مراقبتك عن كثب لمدة 8 أسابيع على الأقل بعد إيقاف إيمبافيلي. قد يؤدي إيقاف العلاج باستخدام إيمبافيلي إلى تكسر خلايا الدم الحمراء بسبب البيلة الهيموغلوبينية الانتيابية الليلية (PNH). تشمل الأعراض والمشاكل التي يمكن أن تحدث بسبب تكسر خلايا الدم الحمراء ما يلي:</p><ul><li>انخفاض مستوى الهيموجلوبين في الدم</li><li>وجود دم في البول</li><li>قصر النفس</li><li>صعوبة البلع</li><li>التعب</li><li>ألم في المعدة (البطن)</li><li>الجلطات الدموية</li><li>ضعف الانتصاب</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يسبب هذا الدواء، كغيره من الأدوية، أعراضا جانبية، رغم أنها لا تصيب الجميع.</p><p>&nbsp;</p><p dir="RTL"><strong>يمكن أن يسبب إيمبافيلي أعراضا جانبية خطيرة بما في ذلك:</strong><strong> </strong></p><p dir="RTL"><u>عدوى خطيرة</u></p><p dir="RTL">إذا واجهت أيًا من أعراض العدوى ،انظر القسم 2 ، فيجب عليك إبلاغ طبيبك على الفور.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><u>ردود الفعل التحسسية</u></p><p dir="RTL">في حالة حدوث تفاعل شديد لفرط الحساسية (على سبيل المثال ، تورم في الوجه ، طفح جلدي) ، انظر القسم ٢ ، توقف عن تسريب إيمبافيلي على الفور واتصل بطبيبك.</p><p>&nbsp;</p><p dir="RTL">إذا لم تكن متأكدًا من الأعراض الجانبية أدناه، فاطلب من الطبيب أن يشرحها لك.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة للغاية </strong>(قد تصيب أكثر من شخص من كل 10 أشخاص):<strong> </strong></p><ul><li>تفاعلات موقع الحقن</li><li>العدوى</li><li>الإسهال</li><li>ألم في المعدة (البطن)</li><li>عدوى الجهاز التنفسي</li><li>ألم في الذراعين، الكفين، الرجلين أو القدمين</li><li>قلة البوتاسيوم في الدم</li><li>التعب</li><li>عدوى فيروسية</li><li>الكحة</li><li>ألم في المفاصل</li><li>الدوار</li><li>الصداع</li><li>الطفح الجلدي</li></ul><p>&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (قد تصيب شخصًا من كل 10 أشخاص):</p><ul><li>ألم بالصدر</li><li>ألم الظهر</li><li>ارتفاع ضغط الدم</li><li>نقص تروية الأمعاء</li><li>الإنتان الصفراوي</li><li>التهاب رئوي بفرط التحسس</li></ul><p>&nbsp;</p><p dir="RTL">إذا تفاقم أي من الأعراض الجانبية، أو إذا لاحظت أي أعراض جانبية غير مدرجة في هذه النشرة، فيرجى إخبار طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">للإبلاغ عن الأعراض الجانبية</p><p>&nbsp;</p><ul dir="rtl"><li>المملكة العربية السعودية:</li></ul><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية<br />- مركز الاتصال الموحد للهيئة العامة للغذاء والدواء: 19999<br />- البريد الإلكتروني: npc.drug@sfda.gov.sa<br />- الموقع الإلكتروني: /https://ade.sfda.gov.sa</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><ul dir="rtl"><li>الإمارات العربية المتحدة:</li></ul><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p dir="RTL">قسم إدارة اليقظة الدوائية والأجهزة الطبية</p><p dir="RTL">الرمز<strong> </strong>البريدي<strong>:</strong> <strong>&nbsp;</strong>1853</p><p dir="RTL">تليفون<strong>:</strong> <strong>&nbsp;&nbsp;</strong>80011111</p><p dir="RTL">البريد الالكتروني: pv@mohap.gov.ae</p><p dir="RTL">قطاع الدواء</p><p dir="RTL">وزارة الصحة ووقاية المجتمع</p><p dir="RTL">دبي</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><ul dir="rtl"><li>دول الخليج الأخرى:</li></ul><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p dir="RTL">الرجاء<strong> </strong>الاتصال<strong> </strong>بالمؤسسات<strong> </strong>والهيئات الوطنية في كل دولة<strong> </strong></p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أحفظ جميع الأدوية بعيداً عن مرأى ومتناول الأطفال.</p><p>لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الكرتونية بعد الاختصار &quot;EXP&quot;. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p>يخزن في الثلاجة (٢ درجة مئوية - ٨ درجة مئوية).</p><p>يرجى تخزين الدواء في علبته الأصلية لحمايته من الضوء.</p><p>لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد في حاجة إليها. ستساعد تلك الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي بيجسيتاكوبلان. كل قارورة تحتوي على ٥٤ ملجم من بيجسيتاكوبلان لكل مل.</p><p>المكونات الأخرى هي: السوربيتول، وحمض الخليك الجليدي، وثلاثي هيدرات أسيتات الصوديوم، وماء للحقن. قد يحتوي إيمبافيلي أيضًا على هيدروكسيد الصوديوم و/أو حمض خليك جليدي إضافي لتعديل الأس الهيدروجيني.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل إيمبافيلي ومحتويات العبوة</strong></p><p>إيمبافيلي هو محلول صافٍ عديم اللون يميل إلى الأصفر قليلاً للتسريب تحت الجلد يتوفر في شكل محلول ١٠٨٠ ملجم لكل ٢٠ مل (٥٤ ملجم/مل) في قارورات أحادية الجرعة سعة ٢٠ مل.</p><p>يتوفر إيمبافيلي في عبوة من قارورة واحدة أو عبوة متعددة من ١ &times; ٨ قارورات.</p><p>قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المخولة بالتسويق والشركة المسؤولة عن التصنيع النهائي:</strong></p><p dir="RTL">سويدش اورفان بيوتيرم اي بي (بوبل)،</p><p dir="RTL">اس اي - ١١٢ ٧٦ ستوكهولم ، السويد</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة</strong><strong> </strong><strong>المصنعة:</strong></p><p dir="RTL">كانجين بيوفارما، ال ال سي</p><p dir="RTL">١١١١ جنوب شارع باكا</p><p dir="RTL">بالتيمور، ام دي ٢١٢٣٠ ، الولايات المتحدة الأمريكية<br />&nbsp;</p><p><strong>&nbsp;مجلس وزراء الصحة العرب:</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:604px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>إن هذا الدواء</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp; الدواء مستحضر يؤثر على صحتك واستهلاكه خلافًا للتعليمات يعرضك للخطر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; اتبع بدقة وصفة الطبيب، وطريقة الاستعمال المنصوص عليها، وتعليمات الصيدلي الذي صرفها لك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; الطبيب والصيدلي هما الخبيران في الدواء، وفي نفعه وضرره.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; لا تكرر صرف الدواء بدون استشارة الطبيب المختص.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; لا تترك الأدوية في متناول الاطفال.</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">مجلس وزراء الصحة العرب</p><p dir="RTL">واتحاد الصيادلة العرب</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت المراجعة الأخيرة لهذه النشرة في فبراير ٢٠٢٤
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EMPAVELI 1080 mg/20 mL (54 mg/mL) solution for infusion, for subcutaneous use.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1080 mg/20 mL (54 mg/mL) in a single-dose vial.

Excipient(s) with known effect

Each mL contains 41 mg sorbitol.
Each vial contains 820 mg of sorbitol.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for infusion.

Clear, colourless to slightly yellowish solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>EMPAVELI is a complement inhibitor indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vaccinate patients against encapsulated bacteria, including <em>Streptococcus pneumoniae</em> and <em>Neisseria meningitidis</em> (serogroups A, C, W, Y, B) according to current ACIP recommendations, and <em>Haemophilus influenzae</em> type B at least 2 weeks prior to initiation of EMPAVELI therapy.</p><p>&nbsp;</p><p>If urgent EMPAVELI therapy is indicated in a patient who is not up to date with vaccines for <em>Streptococcus pneumoniae</em> and <em>Neisseria meningitidis</em> according to ACIP recommendations, and<em> Haemophilus influenzae Type&nbsp;B</em>, provide the patient with antibacterial drug prophylaxis and administer these vaccines as soon as possible.</p><p>&nbsp;</p><p><u>Posology</u></p><p>The recommended dose of EMPAVELI is 1080 mg by subcutaneous infusion twice weekly via a commercially available infusion pump with a reservoir of at least 20 mL.</p><p>&nbsp;</p><p><em>Dosage for patients switching to EMPAVELI from C5 inhibitors </em></p><p>To reduce the risk of hemolysis with abrupt treatment discontinuation:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients switching from eculizumab, initiate EMPAVELI while continuing eculizumab at its current dose. After 4 weeks, discontinue eculizumab before continuing on monotherapy with EMPAVELI.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients switching from ravulizumab, initiate EMPAVELI no more than 4 weeks after the last dose of ravulizumab.</p><p>&nbsp;</p><p><em>Dose Adjustment </em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For lactate dehydrogenase (LDH) levels greater than 2 &times; the upper limit of normal (ULN), adjust the dosing regimen to 1080 mg every three days.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the event of a dose increase, monitor LDH twice weekly for at least 4 weeks.</p><p>&nbsp;</p><p><em>Missed Dose </em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer EMPAVELI as soon as possible after a missed dose. Resume the regular dosing schedule following administration of the missed dose.</p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>The safety and efficacy of EMPAVELI in children with PNH aged 0 to &lt;18 years have not yet been established. No data are available.</p><p>&nbsp;</p><p><em>Elderly </em></p><p>Clinical studies of EMPAVELI did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients.</p><p>&nbsp;</p><p><u>Method of administration </u></p><p>EMPAVELI is for subcutaneous infusion using an infusion pump.</p><p>EMPAVELI is intended for use under the guidance of a healthcare professional. After proper training in subcutaneous infusion, you may self-administer, or your caregiver may administer EMPAVELI, if a doctor determines that it is appropriate.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Refer to the EMPAVELI Patient Information Leaflet and the infusion pump manufacturer&rsquo;s instructions for full preparation and administration information.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use aseptic technique when preparing and administering EMPAVELI.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prior to use&sbquo; allow EMPAVELI to reach room temperature for approximately 30 minutes. Keep the vial in the carton until ready for use to protect from light.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. EMPAVELI is a clear, colorless to slightly yellowish solution. Do not use if the liquid looks cloudy, contains particles, or is dark yellow.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use a needleless transfer device (such as a vial adapter) or a transfer needle to fill the syringe.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rotate infusion sites (i.e., abdomen, thighs, hips, upper arms) from one infusion to the next. Do not infuse where the skin is tender, bruised, red, or hard. Avoid infusing into tattoos, scars, or stretch marks.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If multi-infusion sets are needed, ensure the infusion sites are at least 7.5 cm apart.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The typical infusion time is approximately 30 minutes (if using two infusion sites) or approximately 60 minutes (if using one infusion site).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Discard any unused portion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EMPAVELI is contraindicated:
•	in patients with hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (see Special warnings and precautions for use (4.4)).
•	for initiation in patients with unresolved serious infection caused by encapsulated bacteria including Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B (see Special warnings and precautions for use (4.4)).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Serious Infections Caused by Encapsulated Bacteria </u></p><p>EMPAVELI, a complement inhibitor, increases a patient&rsquo;s susceptibility to serious, life-threatening, or fatal infections caused by encapsulated bacteria including <em>Streptococcus pneumoniae</em>, <em>Neisseria meningitidis</em> (caused by any serogroup, including non-groupable strains), and <em>Haemophilus influenzae </em>type B. Life-threatening and fatal infections with encapsulated bacteria have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors. The initiation of EMPAVELI treatment is contraindicated in patients with unresolved serious infection caused by encapsulated bacteria.</p><p>Complete or update vaccination against encapsulated bacteria at least 2 weeks prior to administration of the first dose of EMPAVELI, for <em>Haemophilus influenzae </em>type B and according to the most current ACIP recommendations for <em>Streptococcus pneumoniae</em> and <em>Neisseria meningitidis</em> for patients receiving a complement inhibitor. Revaccinate patients for <em>Haemophilus influenzae </em>type B every 2 years and in accordance with ACIP recommendations for <em>Streptococcus pneumoniae</em> and <em>Neisseria meningitidis,</em> considering the duration of therapy with EMPAVELI. Note that, ACIP recommends an administration schedule in patients receiving complement inhibitors that differs from the administration schedule in the vaccine prescribing information. If urgent EMPAVELI therapy is indicated in a patient who is not up to date with vaccines against encapsulated bacteria according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer these vaccines as soon as possible. Various durations and regimens of antibacterial drug prophylaxis have been considered, but the optimal durations and drug regimens for prophylaxis and their efficacy have not been studied in unvaccinated or vaccinated patients receiving complement inhibitors, including EMPAVELI. The benefits and risks of treatment with EMPAVELI, as well as the benefits and risks of antibacterial drug prophylaxis in unvaccinated or vaccinated patients, must be considered against the known risks for serious infections caused by encapsulated bacteria.</p><p>Vaccination does not eliminate the risk of serious encapsulated bacterial infections, despite development of antibodies following vaccination. Closely monitor patients for early signs and symptoms of serious infection and evaluate patients immediately if an infection is suspected. Inform patients of these signs and symptoms and instruct patients to seek immediate medical care if these signs and symptoms occur. Promptly treat known infections. Serious infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider interruption of EMPAVELI in patients who are undergoing treatment for serious infections.</p><p>&nbsp;</p><p><u>Infusion-Related Reactions</u></p><p>Systemic hypersensitivity reactions (e.g., facial swelling, rash, urticaria) have occurred in patients treated with EMPAVELI. One patient (less than 1% in clinical studies) experienced a serious allergic reaction which resolved after treatment with antihistamines. If a severe hypersensitivity reaction (including anaphylaxis) occurs, discontinue EMPAVELI infusion immediately, institute appropriate treatment, per standard of care, and monitor until signs and symptoms are resolved.</p><p><strong>&nbsp;</strong></p><p><u>Monitoring PNH Manifestations after Discontinuation of EMPAVELI</u></p><p>After discontinuing treatment with EMPAVELI, closely monitor for signs and symptoms of hemolysis, identified by elevated LDH levels along with sudden decrease in PNH clone size or hemoglobin, or reappearance of symptoms such as fatigue, hemoglobinuria, abdominal pain, dyspnea, major adverse vascular events (including thrombosis), dysphagia, or erectile dysfunction. Monitor any patient who discontinues EMPAVELI for at least 8 weeks to detect hemolysis and other reactions. If hemolysis, including elevated LDH, occurs after discontinuation of EMPAVELI, consider restarting treatment with EMPAVELI.</p><p>&nbsp;</p><p><u>Interference with laboratory tests</u></p><p>There may be interference between silica reagents in coagulation panels and EMPAVELI that results in artificially prolonged activated partial thromboplastin time (aPTT); therefore, avoid the use of silica reagents in coagulation panels.</p><p>&nbsp;</p><p><u>Excipients with known effect</u></p><p><em>Sorbitol content</em></p><p>EMPAVELI 1080&nbsp;mg contains 820&nbsp;mg sorbitol in each vial.</p><p><em>Sodium content</em></p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say, essentially &lsquo;sodiumfree&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>EMPAVELI may cause embryo fetal harm when administered to pregnant women. Pregnancy testing is recommended for females of reproductive potential prior to treatment with EMPAVELI. Advise female patients of reproductive potential to use effective contraception during treatment with EMPAVELI and for 40 days after the last dose.</p><p><u>&nbsp;</u></p><p><u>Risk Summary</u></p><p>There are insufficient data on EMPAVELI use in pregnant women to inform a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with untreated PNH in pregnancy <em>(see Clinical Considerations)</em>. The use of EMPAVELI may be considered following an assessment of the risks and benefits.</p><p>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of major birth defect, loss, or other adverse outcomes.</p><p>&nbsp;</p><p><u>Clinical Considerations</u></p><p><em>Disease-associated maternal and/or fetal/neonatal risk </em></p><p>PNH in pregnancy is associated with adverse maternal outcomes, including worsening cytopenias, thrombotic events, infections, bleeding, miscarriages and increased maternal mortality, and adverse fetal outcomes, including fetal death and premature delivery.</p><p>&nbsp;</p><p><strong>Lactation </strong></p><p><u>Risk Summary</u></p><p>It is not known whether pegcetacoplan is secreted in human milk or whether there is potential for absorption and harm to the infant. There are no data on the effects of pegcetacoplan on milk production. Since many medicinal products are secreted into human milk, and because of the potential for serious adverse reaction in a breastfeeding child, breastfeeding should be discontinued during treatment and for 40 days after the last dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Empaveli has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious Infections Caused by Encapsulated Bacteria <em>(see section 4.4) </em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infusion-Related Reactions <em>(see section 4.4) </em></p><p>&nbsp;</p><p><strong>Clinical Trials Experience </strong></p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>&nbsp;</p><p><u>Paroxysmal Nocturnal Hemoglobinuria </u></p><p><em>Study in Complement-Inhibitor Experienced Adult Patients with PNH (Study APL2-302)</em></p><p>The data described below reflect the exposure &nbsp;in 80 adult patients with PNH who received EMPAVELI (n=41) or eculizumab (n=39) at the recommended dosing regimens for 16 weeks. Serious adverse reactions were reported in 7 (17%) patients with PNH receiving EMPAVELI. The most common serious adverse reaction in patients treated with EMPAVELI was infections (5%). The most common adverse reactions (&ge;10%) with EMPAVELI were injection-site reactions, infections, diarrhea, abdominal pain, respiratory tract infection, viral infection, and fatigue.</p><p>&nbsp;</p><p><strong>Table 1 describes the adverse reactions that occurred in &ge;5% of patients treated with EMPAVELI in Study APL2-302.</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse Reaction </strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>EMPAVELI</strong></p><p><strong>(N=41)</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Eculizumab</strong></p><p><strong>(N=39)</strong></p><p><strong>n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injection-site reaction*</p></td><td style="vertical-align:top"><p>16 (39)</p></td><td style="vertical-align:top"><p>2 (5)</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue*</p></td><td style="vertical-align:top"><p>5 (12)</p></td><td style="vertical-align:top"><p>9 (23)</p></td></tr><tr><td style="vertical-align:top"><p>Chest pain*</p></td><td style="vertical-align:top"><p>3 (7)</p></td><td style="vertical-align:top"><p>1 (3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations </strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Infections*</p></td><td style="vertical-align:top"><p>12 (29)</p></td><td style="vertical-align:top"><p>10 (26)</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory tract infection*</p></td><td style="vertical-align:top"><p>6 (15)</p></td><td style="vertical-align:top"><p>5 (13)</p></td></tr><tr><td style="vertical-align:top"><p>Viral Infection*</p></td><td style="vertical-align:top"><p>5 (12)</p></td><td style="vertical-align:top"><p>3 (8)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>9 (22)</p></td><td style="vertical-align:top"><p>1 (3)</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain*</p></td><td style="vertical-align:top"><p>8 (20)</p></td><td style="vertical-align:top"><p>4 (10)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Back pain*</p></td><td style="vertical-align:top"><p>3 (7)</p></td><td style="vertical-align:top"><p>4 (10)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>3 (7)</p></td><td style="vertical-align:top"><p>9 (23)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Systemic hypertension*</p></td><td style="vertical-align:top"><p>3 (7)</p></td><td style="vertical-align:top"><p>1 (3)</p></td></tr></tbody></table><p>*The following terms were combined:</p><p><strong>Abdominal pain </strong>includes: abdominal pain upper, abdominal discomfort, abdominal pain, abdominal pain lower, abdominal tenderness, epigastric discomfort</p><p><strong>Back pain </strong>includes: back pain, sciatica</p><p><strong>Chest pain </strong>includes: chest discomfort, non-cardiac chest pain, musculoskeletal chest pain, chest pain</p><p><strong>Fatigue </strong>includes: asthenia, lethargy, fatigue</p><p><strong>Infections </strong>include: oral herpes, bacterial infection, fungal infection, gastrointestinal infection, gastrointestinal viral infection, influenza-like illness, nasopharyngitis, pulpitis dental, rhinitis, tonsillitis, tonsillitis bacterial, vulvovaginal mycotic infection, hordeolum, sepsis, furuncle, otitis externa, viral respiratory tract infection, gastroenteritis, upper respiratory tract infection, bronchitis, ear infection, respiratory tract infection, rhinovirus infection, sinusitis, urinary tract infection</p><p><strong>Injection-site reaction </strong>includes: injection-site erythema, injection-site reaction, injection-site swelling, injection-site induration, injection-site bruising, injection-site pain, injection-site pruritus, vaccination-site reaction, administration-site swelling, injection-site hemorrhage, injection-site edema, injection-site warmth, administration-site pain, application-site pain, injection-site mass, injection-site rash, vaccination-site pain</p><p><strong>Respiratory tract infection </strong>includes: influenza-like illness, nasopharyngitis, rhinitis, tonsillitis, viral upper respiratory tract infection, upper respiratory tract infection, respiratory tract infection, sinusitis</p><p><strong>Systemic hypertension </strong>includes: hypertension</p><p><strong>Viral infection </strong>includes: oral herpes, gastrointestinal viral infection, viral upper respiratory tract infection, rhinovirus infection</p><p>&nbsp;</p><p><u>Clinically relevant adverse reactions in less than 5% of patients include:</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intestinal ischemia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Biliary sepsis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity pneumonitis</p><p>&nbsp;</p><p>After the randomized control period, 77 patients continued in the study, and all were treated with EMPAVELI monotherapy at the recommended dosing regimen for up to 48 weeks. Serious adverse reactions were reported in 18 patients (23%).&nbsp; Additional adverse reactions reported in &gt;5% of patients treated with EMPAVELI during the open-label part of the study compared to the randomized controlled part in Table 1 were cough (12%), arthralgia (8%), oropharyngeal pain (8%), pyrexia (8%), pain in extremity (7%), thrombocytopenia (7%), abdominal distension (5%), acute kidney injury (5%), anxiety (5%), and myalgia (5%). One patient (1%) died due to COVID-19 infection.</p><p>&nbsp;</p><p><u>Description of Select Adverse Reactions </u></p><p><em>Injection-Site Reactions </em></p><p>Injection/infusion-site reactions (e.g., erythema, swelling, induration, pruritis, and pain) have been reported during Study APL2-302. These reactions were mild or moderate in severity.</p><p><em>&nbsp;</em></p><p><em>Diarrhea </em></p><p>Seventeen cases of diarrhea have been reported during the 48 weeks. Fifteen of the cases were mild and two were moderate.</p><p><strong>&nbsp;</strong></p><p><em>Study in Complement-Inhibitor Na&iuml;ve Adult Patients with PNH (Study APL2-308)</em></p><p>The data described below reflect the exposure in adult patients with PNH who received EMPAVELI (n=46) or the control arm (supportive care excluding complement inhibitors) (n=18) in Study APL2-308.One patient (2%) who received EMPAVELI died due to septic shock. Serious adverse reactions were reported in 6 (13%) patients with PNH receiving EMPAVELI. The most common adverse reaction (&ge;10%) in patients treated with EMPAVELI were injection site reactions, infections, viral infection, pain in extremity, hypokalemia, arthralgia, dizziness, abdominal pain, rash, and headache.</p><p>Table 2 describes the adverse reactions that occurred in &ge;5% of patients treated with EMPAVELI in Study APL2‑308.</p><p><strong>&nbsp;Table 2: Adverse Reactions Reported in &ge;5% of Patients Treated with EMPAVELI in Study APL2‑308</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td><p><strong>Adverse Reaction</strong></p></td><td style="vertical-align:top"><p><strong>EMPAVELI</strong></p><p><strong>(N=46)</strong></p><p><strong>n (%)</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Exposure Adjusted Rate (per 100 pt yrs)</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Control Arm<sup>a</sup></strong></p><p><strong>(N=18)</strong></p><p><strong>n (%)</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Exposure Adjusted Rate (per 100 pt yrs)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Injection‑site reaction*</p></td><td style="vertical-align:top"><p>12 (26)</p><p>42</p></td><td style="vertical-align:top"><p>0</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td><p>4(9)</p><p>14</p></td><td style="vertical-align:top"><p>0</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Peripheral edema*</p></td><td style="vertical-align:top"><p>3 (7)</p><p>11</p></td><td style="vertical-align:top"><p>0</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and Infestations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Infections*</p></td><td style="vertical-align:top"><p>9 (20)</p><p>32</p></td><td style="vertical-align:top"><p>4 (22)</p><p>74</p></td></tr><tr><td style="vertical-align:top"><p>Viral infection*</p></td><td style="vertical-align:top"><p>6 (13)</p><p>21</p></td><td style="vertical-align:top"><p>2 (11)</p><p>37</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pain in extremity</p></td><td style="vertical-align:top"><p>6 (13)</p><p>21</p></td><td style="vertical-align:top"><p>0</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>5 (11)</p><p>18</p></td><td style="vertical-align:top"><p>0</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal pain</p></td><td style="vertical-align:top"><p>3 (7)</p><p>11</p></td><td style="vertical-align:top"><p>0</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hypokalemia</p></td><td style="vertical-align:top"><p>6 (13)</p><p>21</p></td><td style="vertical-align:top"><p>2 (11)</p><p>37</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>5 (11)</p><p>18</p></td><td style="vertical-align:top"><p>0</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>5 (11)</p><p>18</p></td><td style="vertical-align:top"><p>0</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>3 (7)</p><p>11</p></td><td style="vertical-align:top"><p>0</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain*</p></td><td style="vertical-align:top"><p>5 (11)</p><p>18</p></td><td style="vertical-align:top"><p>1 (6)</p><p>18</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rash*</p></td><td style="vertical-align:top"><p>5(11)</p><p>18</p></td><td style="vertical-align:top"><p>0</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Ecchymosis</p></td><td style="vertical-align:top"><p>3 (7)</p><p>11</p></td><td style="vertical-align:top"><p>0</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Erythema</p></td><td style="vertical-align:top"><p>3 (7)</p><p>11</p></td><td style="vertical-align:top"><p>0</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>3 (7)</p><p>11</p></td><td style="vertical-align:top"><p>1 (6)</p><p>18</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cough*</p></td><td style="vertical-align:top"><p>4 (9)</p><p>14</p></td><td style="vertical-align:top"><p>0</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Epistaxis</p></td><td style="vertical-align:top"><p>3 (7)</p><p>11</p></td><td style="vertical-align:top"><p>0</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>3 (7)</p><p>11</p></td><td style="vertical-align:top"><p>0</p><p>0</p></td></tr></tbody></table><p><sup>a</sup>Control Arm = supportive care (excluding complement inhibitors)</p><p>EMPAVELI (N=46) group includes patients who received EMPAVELI at any point during the study, including patients randomized to EMPAVELI (N=35) and patients randomized to the control arm and crossed over to EMPAVELI treatment (N=11).</p><p>*The following terms were combined:</p><p><strong>Infections </strong>include<strong>: </strong>acne pustular, anal abscess, cellulitis, gastroenteritis, helicobacter gastritis, hordeolum, nasopharyngitis, esophageal candidiasis, pharyngitis, septic shock, tuberculosis, upper respiratory tract infection, urinary tract infection enterococcal, vaginal infection, pneumocystitis jirovecii pneumonia, pulmonary tuberculosis, urinary tract infection</p><p><strong>Abdominal pain </strong>includes: abdominal pain, abdominal pain upper.</p><p><strong>Injection site reaction </strong>includes: injection site bruising, injection site hemorrhage, injection site swelling, application site reaction, infusion site pruritus, injection site erythema, injection site rash, puncture site reaction.</p><p><strong>Viral infection</strong> includes<strong>:</strong> viral infection, covid-19, covid-19 pneumonia, coronavirus test positive, herpes virus, influenza</p><p><strong>Peripheral edema </strong>includes<strong>:</strong> peripheral swelling, edema peripheral</p><p><strong>Headache </strong>includes<strong>:</strong> headache, migraine</p><p><strong>Rash </strong>includes<strong>:</strong> rash, maculo-papular rash, dermatitis</p><p><strong>Cough </strong>includes<strong>:</strong> cough, allergic cough</p><p>&nbsp;</p><p><strong>To report any side effect(s): </strong></p><ul><li><strong>Saudi Arabia:&nbsp;</strong></li></ul><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><ul><li><strong>United Arab Emirates:</strong></li></ul><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Pharmacovigilance and Medical Device Section:<br />Postal code: 1853<br />Telephone: 80011111<br />E-mail: pv@mohap.gov.ae</p><p>Drug Department<br />Ministry of Health and Prevention<br />Dubai</p></td></tr></tbody></table><p>&nbsp;</p><ul><li><strong>Other GCC States: </strong></li></ul><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>- Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No case of overdose has been reported to date.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressants, Complement inhibitors, ATC code: L04AJ03</p><p>EMPAVELI contains pegcetacoplan, a complement inhibitor. Pegcetacoplan is a symmetrical molecule comprised of two identical pentadecapeptides covalently bound to the ends of a linear 40-kiloDalton (kDa) PEG molecule. The peptide portions of pegcetacoplan contain 1-methyl-L-tryptophan (Trp(Me)) in position 4 and amino(ethoxyethoxy)acetic acid (AEEA) in position 14.</p><p>The molecular weight of pegcetacoplan is approximately 43.5 kDa. The molecular formula is C1970H3848N50O947S4. The structure of pegcetacoplan is shown below.</p><p><img src="data:image/png;base64,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" alt="" width="605" height="156" vspace="0" hspace="0" border="0" style="width:605px;height:156px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p><strong>Mechanism of Action </strong></p><p>Pegcetacoplan binds to complement protein C3 and its activation fragment C3b, thereby regulating the cleavage of C3 and the generation of downstream effectors of complement activation. In PNH, extravascular hemolysis (EVH) is facilitated by C3b opsonization while intravascular hemolysis (IVH) is mediated by the downstream membrane attack complex (MAC). Pegcetacoplan acts proximally in the complement cascade controlling both C3b-mediated EVH and terminal complement-mediated IVH.</p><p><strong>&nbsp;</strong></p><p><strong>Pharmacodynamics </strong></p><p>In patients with PNH administered multiple doses of pegcetacoplan the mean C3 concentration increased from 0.94 g/L at baseline to 3.80 g/L at Week 16 and sustained through week 48 (Study APL2-302). In study APL2-308, the mean C3 concentration increased from 0.95 g/L at baseline to 3.56 g/L at Week 26<em>.</em> The percentage of PNH Type II + III RBCs increased from 66.2% at baseline&nbsp; to 93.9% at Week 16 and sustained through Week 48 (Study APL2-302). In Study APL2-308, the mean percentage of PNH Type II + III RBCs increased from 42.4% at baseline to 90.0% at Week 26. The mean percentage of PNH Type II + III RBCs with C3 deposition decreased from 17.8% at baseline&nbsp; to 0.20% at Week 16 &nbsp;and sustained through Week 48 (Study APL2-302). In Study APL2-308, the mean percentage of PNH Type II + III RBCs with C3 deposition decreased from 2.85% at baseline to 0.09% at Week 26.</p><p>&nbsp;</p><p><u>Cardiac Electrophysiology </u></p><p>At the recommended dose of EMPAVELI, no large mean increases in QTc interval (i.e., greater than 20 msec) were observed.</p><p>&nbsp;</p><p><strong>Clinical studies Paroxysmal Nocturnal Hemoglobinuria </strong></p><p>The efficacy and safety of EMPAVELI in patients with PNH were assessed in two open-label, randomized-controlled Phase 3 studies&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (StudyAPL2-302 NCT03500549) and study APL2-308 (NCT04085601). All patients who completed the studies were eligible to enroll in a separate long-term extension study. In both studies, patients were vaccinated against <em>Streptococcus pneumoniae</em>, <em>Neisseria meningitidis</em> types A, C, W, Y, and B, and <em>Haemophilus influenzae</em> type B (Hib), either within 2&nbsp;years prior to Day&nbsp;1 or within 2&nbsp;weeks after starting treatment with EMPAVELI. Patients vaccinated after initiation of treatment with EMPAVELI received prophylactic treatment with appropriate antibiotics until 2&nbsp;weeks after vaccination. In addition, prophylactic antibiotic therapy was administered at the discretion of the investigator in accordance with local treatment guidelines for patients with PNH receiving treatment with a complement inhibitor.</p><p>A dose of 1,080 mg twice weekly was used for patients randomized to the EMPAVELI group of each study. If required, the dose of EMPAVELI could be adjusted to 1,080&nbsp;mg every 3&nbsp;days. EMPAVELI was administered as a subcutaneous infusion; the infusion time was approximately 20 to 40&nbsp;minutes.</p><p><em>Study in Complement-Inhibitor Experienced Adult Patients with PNH (Study APL2-302)</em></p><p>The study enrolled patients with PNH who had been treated with a stable dose of eculizumab for at least the previous 3 months and with Hb levels less than 10.5 g/dL.</p><p>Eligible patients entered a 4-week run-in period during which they received EMPAVELI 1080 mg subcutaneously twice weekly in addition to their current dose of eculizumab. Patients were then randomized in a 1:1 ratio to receive either 1080 mg of EMPAVELI twice weekly or their current dose of eculizumab through the duration of the 16-week randomized controlled period (RCP).</p><p>Randomization was stratified based on the number of packed red blood cell (PRBC) transfusions within the 12 months prior to Day -28 (&lt;4; &ge;4) and platelet count at screening (&lt;100,000/mm3; &ge;100,000/mm3). Following completion of the RCP, all patients entered a 32-week open-label period (OLP) and received monotherapy with EMPAVELI. Patients initially randomized to eculizumab entered a second 4-week run-in period during which they received EMPAVELI in addition to eculizumab before continuing on to receive EMPAVELI monotherapy. All patients who completed the 48-week period were eligible to enroll in a separate long-term extension study.</p><p>A total of 80 patients were randomized to receive treatment, 41 to EMPAVELI and 39 to eculizumab. Demographics and baseline disease characteristics were generally well balanced between treatment groups (see Table 2). The median times from PNH diagnosis to Day -28 were 6.0 and 9.7 years, respectively, for EMPAVELI and eculizumab. The baseline mean total PNH RBC clone sizes (Type III) were 47% for EMPAVELI and 50% for eculizumab. Twenty-nine percent and 23% of patients had a history of major adverse vascular events, and 37% and 26% had a history of thrombosis for patients receiving EMPAVELI or eculizumab, respectively. Within 28 days prior to the first dose of EMPAVELI or eculizumab, respectively, 34% and 31% of patients used anti-thrombotic agents (anti-platelet and/or anticoagulants). During Study APL2-302, 37% and 36% of patients on EMPAVELI and eculizumab, respectively, used antithrombotic agents. A total of 38 patients in the group treated with EMPAVELI and 39 patients in the eculizumab group completed the 16-week RCP and continued into the 32-week OLP. Because of adverse reactions of hemolysis, 3 patients were discontinued from the EMPAVELI group during the RCP. Two out of 41 patients in the EMPAVELI group needed the dose adjustment to 1080 mg every 3 days.</p><p><strong>&nbsp;</strong></p><p><strong>Table 3: Patient Baseline Demographics and Characteristics in Study APL2-302</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Parameter </strong></p></td><td style="vertical-align:top"><p><strong>Statistics </strong></p></td><td style="vertical-align:top"><p><strong>EMPAVELI (N=41) </strong></p></td><td style="vertical-align:top"><p><strong>Eculizumab (N=39) </strong></p></td></tr><tr><td style="vertical-align:top"><p>Age (years)</p></td><td style="vertical-align:top"><p>Mean (SD)</p></td><td style="vertical-align:top"><p>50.2 (16.3)</p></td><td style="vertical-align:top"><p>47.3 (15.8)</p></td></tr><tr><td style="vertical-align:top"><p>Sex</p><p>Female</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>27 (65.9)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>22 (56.4)</p></td></tr><tr><td style="vertical-align:top"><p>Race</p><p>Asian</p><p>Black or African American</p><p>White</p><p>Other</p><p>Not reported</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>n (%)</p><p>n (%)</p><p>n (%)</p><p>n (%)</p><p>n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>5 (12.2)</p><p>2 (4.9)</p><p>24 (58.5)</p><p>0</p><p>10 (24.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7 (17.9)</p><p>0</p><p>25 (64.1)</p><p>1 (2.6)</p><p>6 (15.4)</p></td></tr><tr><td style="vertical-align:top"><p>Ethnicity</p><p>Hispanic or Latino</p><p>Not Hispanic or Latino</p><p>Not reported</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>n (%)</p><p>n (%)</p><p>n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2 (4.9)</p><p>29 (70.7)</p><p>10 (24.4</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>1 (2.6)</p><p>32 (82.1)</p><p>6 (15.4)</p></td></tr><tr><td style="vertical-align:top"><p>Hemoglobin level (g/dL)</p></td><td style="vertical-align:top"><p>Mean (SD)</p></td><td style="vertical-align:top"><p>8.7 (1.1)</p></td><td style="vertical-align:top"><p>8.7 (0.9)</p></td></tr><tr><td style="vertical-align:top"><p>Absolute reticulocyte count (109 cells/L)</p></td><td style="vertical-align:top"><p>Mean (SD)</p></td><td style="vertical-align:top"><p>218 (75.0)</p></td><td style="vertical-align:top"><p>308.6 (284.8)</p></td></tr><tr><td style="vertical-align:top"><p>LDH level (U/L)</p></td><td style="vertical-align:top"><p>Mean (SD)</p></td><td style="vertical-align:top"><p>257.5 (97.7)</p></td><td style="vertical-align:top"><p>308.6 (284.8)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Number of transfusions in last 12 months prior to Day -28</p><p>&lt;4</p><p>&ge;4</p></td><td style="vertical-align:top"><p>Mean (SD)</p></td><td style="vertical-align:top"><p>6.1 (7.3)</p></td><td style="vertical-align:top"><p>6.9 (7.7)</p></td></tr><tr><td style="vertical-align:top"><p>n (%)</p></td><td style="vertical-align:top"><p>20 (48.8)</p></td><td style="vertical-align:top"><p>16 (41.0)</p></td></tr><tr><td style="vertical-align:top"><p>n (%)</p></td><td style="vertical-align:top"><p>21 (51.2)</p></td><td style="vertical-align:top"><p>23 (59.0)</p></td></tr></tbody></table><p>&nbsp;</p><p>The efficacy of EMPAVELI was based on change from baseline to Week 16 (during RCP) in hemoglobin level. Baseline was defined as the average of measurements recorded prior to taking the first dose of EMPAVELI. Supportive efficacy data included transfusion avoidance, defined as the proportion of patients who did not require a transfusion during the RCP, and change from baseline to Week 16 in absolute reticulocyte count (ARC).</p><p>EMPAVELI was superior to eculizumab for the change from baseline in hemoglobin level at Week 16 (<em>p</em>&lt;0.0001). The adjusted mean change from baseline in hemoglobin level was 2.37 g/dL in the group treated with EMPAVELI versus -1.47 g/dL in the eculizumab group (Figure 1), demonstrating an adjusted mean increase of 3.84 g/dL with EMPAVELI compared to eculizumab at Week 16 (95% CI, 2.33-5.34).</p><p>&nbsp;</p><p><strong>Figure 1: Adjusted Mean (&plusmn; SE) Change from Baseline to Week 16 in Hemoglobin (g/dL)* in Study APL2-302*&nbsp;</strong><img alt="" width="557" height="246" src="data:image/png;base64,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" /></p><p>*Treatment effect estimates from a mixed model are shown. The mixed model contained the categorical effects of treatment, visit, treatment by visit interaction, and stratification factors (transfusion history and platelet count at screening), and the continuous covariate of baseline value.</p><p>Non-inferiority was demonstrated in the endpoints of transfusion avoidance and change from baseline in ARC at week 16.</p><p>The adjusted means, treatment differences, and confidence intervals (CIs) for additional efficacy results are shown in Table 4.</p><p><strong>&nbsp;</strong></p><p><strong>Table 4: Additional Efficacy Results at week 16 in study APL2-302</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>EMPAVELI</strong></p><p><strong>(N=41)</strong></p></td><td style="vertical-align:top"><p><strong>Eculizumab</strong></p><p><strong>(N=39)</strong></p></td><td style="vertical-align:top"><p><strong>Difference</strong></p><p><strong>(95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Transfusion avoidance</strong>, n (%)</p></td><td style="vertical-align:top"><p>35 (85%)</p></td><td style="vertical-align:top"><p>6 (15%)</p></td><td style="vertical-align:top"><p>63%* (48%, 77%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Change from baseline in ARC </strong>(10<sup>9 </sup>cells/L), LS&dagger; mean (SE)&Dagger;</p></td><td style="vertical-align:top"><p>-136 (6.5)</p></td><td style="vertical-align:top"><p>28 (11.9)</p></td><td style="vertical-align:top"><p>-164 (-189.9, -137.3)</p></td></tr></tbody></table><p>*Difference in percentages and 95% CI were based on the stratified Miettinen&ndash;Nurminen method.</p><p>&dagger;LS = Least square</p><p>&Dagger;SE = Standard error</p><p>&nbsp;</p><p>Efficacy was generally similar across subgroups based on sex, race, and age.</p><p>All 77 patients who completed the RCP entered the 32‑ week OLP, during which all patients received EMPAVELI, resulting in a total exposure of up to 48 weeks. Between Week 16 and Week 48, 10 patients discontinued the study, all due to adverse reactions, and thirteen patients had a dose adjustment to 1,080 mg every three days. The efficacy results at Week 48 were generally consistent with those at Week 16.<br /><br /><em>Study in Complement-Inhibitor Na&iuml;ve Adult Patients with PNH (Study APL2-308)</em></p><p>Study APL2-308 enrolled patients with PNH who had not been treated with any complement inhibitor within 3 months prior to enrollment and with Hb levels less than the lower limit of normal (LLN). Eligible patients were randomized in a 2:1 ratio to receive EMPAVELI or supportive care [excluding complement inhibitors (e.g., transfusions, corticosteroids, supplements such as iron, folate, and vitamin B<sub>12</sub>), hereafter referred to as the control arm] through the duration of the 26‑week treatment period. Randomization was stratified based on the number of packed red blood cell (PRBC) transfusions within the 12&nbsp;months prior to Day&nbsp;‑28 (&lt;4; &ge;4). At any point during the study, a patient assigned to the control arm treatment group who had Hb levels &ge;2 g/dL below baseline or presented with a PNH associated thromboembolic event was offered cross-over to EMPAVELI for the remainder of the study.</p><p>A total of 53&nbsp;patients were randomized, 35 to EMPAVELI and 18 to the control arm. Demographics and baseline disease characteristics were generally well balanced between treatment groups (see Table&nbsp;4). The mean times from PNH diagnosis to Day 1 were 5.7 and 5.5&nbsp;years, respectively, for EMPAVELI and the control arm. The baseline mean total PNH RBC clone sizes (Type III) were 31% for EMPAVELI and 28% for the control arm. In the EMPAVELI group, 2.9% of patients had a history of major adverse vascular events. Two patients (5.7%) in the EMPAVELI group and 3 patients (16.7%) in the control arm group had a history of at least 1 type of thrombosis. Within 28&nbsp;days prior to the first dose of EMPAVELI or the control arm, respectively, 17.1% and 27.8% of patients used anti‑thrombotic agents (anti‑platelet and/or anticoagulants). During Study APL2‑308, 8.6% and 0% of patients on EMPAVELI and the control arm, respectively, used antithrombotic agents. Eleven of 18 patients randomized to the control transitioned to cross-over therapy with EMPAVELI due to a decreased Hb level &ge;2 g/dL below baseline. Three patients treated with EMPAVELI required dose adjustment to 1,080&nbsp;mg every 3&nbsp;days. Three patients (5.7%; two patients in the EMPAVELI group and one patient in the control arm group) discontinued the study, none due to an adverse reaction.</p><p>&nbsp;</p><p>Table 5:<em> </em>Patient Baseline Demographics and Characteristics in Study APL2-308</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td><p><strong>Parameter</strong></p></td><td><p><strong>Statistics</strong></p></td><td><p><strong>EMPAVELI<br />(N=35)</strong></p></td><td><p><strong>Control Arm<sup>a</sup></strong></p><p><strong>&nbsp;<br />(N=18)</strong></p></td></tr></thead><tbody><tr><td><p>Age (years)</p></td><td><p>Mean (SD)</p></td><td><p>42.2 (12.7)</p></td><td><p>49.1 (15.6)</p></td></tr><tr><td><p>Sex</p><p>Female</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>16 (45.7)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8 (44.4)</p></td></tr><tr><td style="vertical-align:top"><p>Race</p><p>American Indian or Alaska&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Native</p><p>Asian</p><p>Black or African American</p><p>Other</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>n (%)</p><p>&nbsp;</p><p>n (%)</p><p>n (%)</p><p>n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>9 (25.7)</p><p>&nbsp;</p><p>23 (65.7)</p><p>2 (5.7)</p><p>1 (2.9)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2 (11.1)</p><p>&nbsp;</p><p>16 (88.9)</p><p>0</p><p>0</p></td></tr><tr><td><p>Ethnicity</p><p>Hispanic or Latino</p><p>Not Hispanic or Latino</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>n (%)</p><p>n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>12 (34.3)</p><p>23 (65.7)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2 (11.1)</p><p>16 (88.9)</p></td></tr><tr><td><p>Hemoglobin level (g/dL)</p></td><td><p>Mean (SD)</p></td><td><p>9.4 (1.4)</p></td><td><p>8.7 (0.8)</p></td></tr><tr><td style="vertical-align:top"><p>Absolute reticulocyte count (10<sup>9</sup>&nbsp;cells/L)</p></td><td><p>Mean (SD)</p></td><td><p>230.2 (81.0)</p></td><td><p>180.3 (109.1)</p></td></tr><tr><td style="vertical-align:top"><p>LDH level (U/L)</p></td><td><p>Mean (SD)</p></td><td><p>2151.0 (909.4)</p></td><td><p>1945.9 (1003.7)</p></td></tr><tr><td><p>Number of transfusions in last 12&nbsp;months prior to Day ‑28</p></td><td><p>Mean (SD)</p></td><td><p>3.9 (4.4)</p></td><td><p>5.1 (5.0)</p></td></tr><tr><td><p>&lt;4</p></td><td><p>n (%)</p></td><td><p>21 (60.0)</p></td><td><p>8 (44.4)</p></td></tr><tr><td><p>&ge;4</p></td><td><p>n (%)</p></td><td><p>14 (40.0)</p></td><td><p>10 (55.6)</p></td></tr></tbody></table><p><sup>a</sup>Control Arm = supportive care (excluding complement inhibitors)</p><p>&nbsp;</p><p>The efficacy of EMPAVELI was based on the percentage of patients achieving hemoglobin stabilization, defined as avoidance of a &gt;1 g/dL decrease in hemoglobin levels from baseline in the absence of transfusion, and the change from baseline in LDH level. Supportive efficacy data included change from baseline in absolute reticulocyte count (ARC), change from baseline in hemoglobin, and transfusion avoidance, defined as the proportion of patients who did not require a transfusion through Week 26. Baseline was defined as the average of measurements recorded prior to taking the first dose of EMPAVELI or prior to randomization to the control arm treatment group.</p><p>Efficacy results are shown in Table&nbsp;6 below.</p><p><br /><strong>Table 6: Efficacy Results During the 26-Week Study in Study APL2-308</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>EMPAVELI<br />(N=35)</strong></p></td><td style="vertical-align:top"><p><strong>Control Arm<sup>a</sup></strong></p><p><strong>&nbsp;</strong></p><p><strong>(N=18)</strong></p></td><td style="vertical-align:top"><p><strong>Difference<br />(95% CI)</strong></p><p><strong>p-value</strong></p><p>&nbsp;</p></td></tr></thead><tbody><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Hemoglobin Stabilization<sup>&sect;</sup> </strong>(n, %)</p></td><td><p>30 (85.7%)</p></td><td><p>0 (0%)</p></td><td><p>73% (57%, 89%)</p><p>p&lt;0.0001*</p></td></tr><tr><td><p><strong>Change from Baseline in LDH<sup>b</sup> </strong>(LS<sup>&dagger;</sup> Mean CFB, SE<sup>&Dagger;</sup>)</p></td><td><p>‑1870 (101.0)</p></td><td><p>-400 (313.0)</p></td><td><p>‑1470 (‑2113.4, ‑827.3)</p><p>p&lt;0.0001</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Change from baseline in ARC<sup>b</sup> </strong></p><p>(LS<sup>&dagger;</sup> Mean CFB, SE<sup>&Dagger;</sup>)</p></td><td><p>-123 (9.2)</p></td><td><p>-19 (25.2)</p></td><td><p>‑103 (‑158.9, ‑48.7)</p><p>p = 0.0002</p></td></tr><tr><td><p><strong>Change from baseline in Hb<sup>b</sup></strong></p><p>(LS<sup>&dagger;</sup> Mean CFB, SE<sup>&Dagger;</sup>)</p></td><td><p>2.9 (0.38)</p></td><td><p>0.3 (0.76)</p></td><td><p>2.7 (0.99, 4.35)</p><p>p = 0.0019</p></td></tr><tr><td><p><strong>Transfusion Avoidance<sup>&sect;</sup> </strong></p><p>(n, %)</p></td><td><p>32 (91%)</p></td><td><p>1 (6%)</p></td><td><p>72% (56%, 89%)</p><p>p&lt;0.0001*</p></td></tr></tbody></table><p><sup>a</sup> Control Arm= supportive care (excluding complement inhibitors)</p><p><sup>b</sup> The post baseline missing values (including the values after cross-over from the control arm) are imputed using a multiple imputation method.</p><p>Data collected after cross-over from the control arm is excluded in analyses.</p><p><sup>&sect;</sup>Patients who crossed over from the control arm group to the EMPAVELI group, withdrew from the study, or were lost to follow up are considered as failing to achieve the criteria.</p><p>*p-value is obtained by stratified Cochran-Mantel-Haenszel test.</p><p><sup>&dagger;</sup>LS&nbsp;=&nbsp;Least square</p><p><sup>&Dagger;</sup>SE&nbsp;=&nbsp;Standard error</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In patients with PNH, the serum pegcetacoplan concentrations achieved steady state approximately 4 to 6 weeks following the first dose. The exposure of pegcetacoplan increased proportionally over a dose range from 45 to 1,440 mg (0.04 to 1.33 times the approved recommended dose). The mean (CV%) trough serum concentration observed at Week 16 was 706 (15.1%) mcg/mL and sustained through Week 48 (Study APL2-302). In Study APL2-308, mean (CV%) trough serum concentration was 744 (25.5%) mcg/mL at Week 26.</p><p><u>Absorption </u></p><p>The median Tmax of pegcetacoplan is between 108 and 144 hours (4.5 to 6.0 days) after a single dose.</p><p><u>Distribution </u></p><p>The mean (CV%) volume of distribution of pegcetacoplan is approximately 3.98 L (35%) in patients with PNH.</p><p><u>Elimination </u></p><p>The estimated mean (CV%) of clearance (CL) is 0.36 L/day (30%) and median effective half-life of elimination (t1/2) is 8.6 days in patients with PNH.</p><p><u>Metabolism </u></p><p>Pegcetacoplan is expected to be metabolized into small peptides and amino acids by catabolic pathways.</p><p><u>Specific Populations </u></p><p>There were no clinically significant differences on the pharmacokinetics of pegcetacoplan based on age (19 to 81 years old), sex, race (Asian vs. non-Asian), renal impairment, and hepatic function as evaluated by total bilirubin (0.06-8.8 mg/dL), albumin (3.0-5.5 g/dL), aspartate aminotransferase (6.0-302 IU/L), or alanine aminotransferase (4.0-209 IU/L).</p><p>&nbsp;</p><p><strong>Immunogenicity</strong></p><p>There is insufficient information to characterize the anti-drug antibody response to EMPAVELI and the effects of anti-drug antibodies on pharmacokinetics, pharmacodynamics, safety, or effectiveness of pegcetacoplan products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Carcinogenesis, Mutagenesis, Impairment of Fertility</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Long-term animal carcinogenicity studies of pegcetacoplan have not been conducted.</p><p>Pegcetacoplan was not mutagenic when tested in an <em>in vitro </em>bacterial reverse mutation (Ames) and was not genotoxic in an <em>in vitro </em>assay in human TK6 cells or in an <em>in vivo </em>micronucleus assay in mice.</p><p>Effects of pegcetacoplan on fertility have not been studied in animals. There were no microscopic abnormalities in male or female reproductive organs in toxicity studies in rabbits and monkeys.</p><p>Animal reproduction studies with pegcetacoplan were conducted in cynomolgus monkeys. Pegcetacoplan treatment of pregnant cynomolgus monkeys at a subcutaneous dose of 28 mg/kg/day (2.9 times human exposure based on AUC) from the gestation period through parturition resulted in a statistically significant increase in abortions and stillbirths compared to controls. No increase in abortions or stillbirths occurred at a dose of 7 mg/kg/day (1.3 times human exposure based on AUC). No maternal toxicity or teratogenic effects were observed in offspring delivered at term. No developmental effects were observed in infants up to 6 months postpartum. Systemic exposure to pegcetacoplan of less than 1% of maternal levels was detected in fetuses from monkeys treated with 28 mg/kg/day from the period of organogenesis through the second trimester.</p><p>Pegcetacoplan was detectable in milk of lactating monkeys at less than 1% concentration of serum levels but was not detectable in the serum of nursing infants.</p><p>&nbsp;</p><p><u>Animal Toxicology and/or Pharmacology</u></p><p>In toxicology studies in rabbits and cynomolgus monkeys, epithelial vacuolation and infiltrates of vacuolated macrophages were observed in multiple tissues, including the renal tubules, following daily subcutaneous doses of pegcetacoplan up to 7 times the human dose. These findings are attributable to uptake of the PEG moieties of pegcetacoplan. Renal degeneration was observed microscopically in rabbits at exposures (Cmax and AUC) less than those for the human dose, and in monkeys at exposures approximately 2.7-fold those for the human dose. The clinical significance of these findings is uncertain.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each mL of solution contains 54 mg of pegcetacoplan, 41 mg of sorbitol, 0.384 mg of glacial acetic acid, 0.490 mg of sodium acetate trihydrate, and Water for Injection USP. EMPAVELI may also contain sodium hydroxide and/or additional glacial acetic acid for adjustment to a target pH of 5.0.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                30 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&nbsp;&deg;C &ndash; 8&nbsp;&deg;C).</p><p>Store in the original package to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>EMPAVELI solution for infusion is a clear, colorless to slightly yellowish aqueous solution for subcutaneous infusion supplied as 1080 mg/20 mL (54 mg/mL) solution in 20-mL single-dose vials.</p><p>EMPAVELI is available in 20-mL single-dose vials individually packaged in cartons that are supplied in 8-count convenience cartons.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorisation Holder & Batch Releaser:
Swedish Orphan Biovitrum AB (publ)
SE-112 76 Stockholm
Sweden

Manufacturer:
Cangene BioPharma, LLC
1111 South Paca Street
Baltimore, MD 21230, USA
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08 Feb 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>